Switch View
© PR Newswire
20.10.2025
ISIN: CNE1000048G6
Remegen Co., Ltd.
9995
LISTED
HKSE
ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
News Preview
BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by RemeGen Co., Ltd. was...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
NUTX Investors Have Opportunity to Lead Nutex Health Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nutex Health Inc. ("Nutex" or "the Company") (NASDAQ: NUTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 p...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US30161Q1040
Exelixis Inc
EXEL
LISTED
NASDAQ
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). As previously announced, the stud...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
20.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
20.10.2025
ISIN: KYG0330A1013
Alphamab Oncology
9966
LISTED
HKSE
Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer
News Preview
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted another breakthrough therapy design...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KYG0330A1013
Alphamab Oncology
9966
LISTED
HKSE
Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025
News Preview
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ovarian cancer (OC) and HER2-positive metastatic colorectal cancer (mCRC...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US6323071042
Natera Inc
NTRA
LISTED
NASDAQ
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 IMvigor011 clinical trial in muscle-invasive bladder cancer (MIBC). The findings demonstrate that Signatera can expand the adjuvant treatment window and guide the use of adjuvant atezolizumab (Tec...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
News Preview
Basel, 20 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III IMvigor011 study evaluating Tecentriq® (atezolizumab) as an adjuvant treatment for people with muscle-invasive bladder cancer (MIBC) who are at risk of recurrence after surgery (cystectomy) and have detectable circulating tumour DNA (ctDN...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
News Preview
Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
News Preview
Basel, 20 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro®(obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy, as well as a shorter 90-minute infusion time after the first infusion, for el...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
20.10.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
BAX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options
If you suffered losses in Baxter between February 23, 2022 and July 30, 2025 and would...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KYG1996C1006
CARsgen Therapeutics Holdings Limited
2171
LISTED
HKSE
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
News Preview
SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial of satricabtagene autoleucel ("satri-cel", CT041) (an autologous C...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: JP3942400007
Astellas Pharma Inc
45030
LISTED
XJPX
IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
News Preview
In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area
Study results found no new safety signals and no cases of retinal vasculitis or occlu...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US03969F1093
Arcus Biosciences Inc
RCUS
LISTED
NYSE
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
News Preview
Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences, Inc. (NYSE:RCUS, “Arcus”) announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International Nonproprietary Name; development code: AB521), an investigational small molecule HIF (Hypoxia Inducible Factor)-2α inhibitor, in Japan and certain o...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: SE0000872095
Swedish Orphan Biovitrum AB (publ)
SOBI
LISTED
STO
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
News Preview
STOCKHOLM, Oct. 19, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today a revised full year outlook for 2025 in response to recent developments. As a result of this announcement, Sobi will make adjustments to its financial reporting schedule such that it will announce its th...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: SE0000872095
Swedish Orphan Biovitrum AB (publ)
SOBI
LISTED
STO
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
News Preview
STOCKHOLM, Oct. 19, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today a revised full year outlook for 2025 in response to recent developments. As a result of this announcement, Sobi will make adjustments to its financial reporting schedule such that it will announce its th...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
News Preview
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (P...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
NEW YORK, Oct. 19, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) and certain of its officers....
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: KYG0146B1032
Akeso Inc
9926
LISTED
HKSE
Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025
News Preview
HONG KONG, Oct. 19, 2025 /PRNewswire/ -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) . COMPASSION-15 is a Phase III clinical trial evaluating cadonilimab, Akeso's first-in-cl...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: KYG0146B1032
Akeso Inc
9926
LISTED
HKSE
HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
News Preview
Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001.
The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24 months), indicating significantly prolonged progression-free survival with ivonescimab combination therap...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
News Preview
Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients
New findings from this investigational study build on the strength of RYBREVANT® (amivantamab-vmjw) in non-small cell lung cancer and broadens its potential across addi...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US86627T1088
Summit Therapeutics Inc
SMMT
LISTED
NASDAQ
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented today as par...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: JP3475350009
Daiichi Sankyo Co Ltd
45680
LISTED
XJPX
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial
News Preview
Initial results from the dose escalation part of the first-in-human phase 1/2 trial of DS-3939 demonstrated promising clinical activity in patients with previously treated advanced solid tumors refractory to standard treatment. These data were presented today during a proffered paper session (917O) at the 2025 European Society for Medical Oncology...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
News Preview
Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer. These data were presented today during a late-breaking proffered...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US3755581036
Gilead Sciences Inc
GILD
LISTED
NASDAQ
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead’s leadership in a...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.10.2025
ISIN: US76029N1063
Replimune Group Inc
REPL
LISTED
NASDAQ
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
News Preview
WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the Euro...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US2183521028
Corcept Therapeutics Inc
CORT
LISTED
NASDAQ
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
News Preview
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacoril...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
News Preview
Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also kn...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US3755581036
Gilead Sciences Inc
GILD
LISTED
NASDAQ
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Trodelvy® (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-neg...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: JP3475350009
Daiichi Sankyo Co Ltd
45680
LISTED
XJPX
DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
News Preview
Positive results from the TROPION-Breast02 phase 3 trial showed DATROWAY® (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as first-line treatment for p...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
News Preview
Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation. In treatment-naïve patients, the median overall survival (OS) was 47.6 mon...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: KYG1996C1006
CARsgen Therapeutics Holdings Limited
2171
LISTED
HKSE
Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia
News Preview
SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Primary plasma cell leukemia (pPCL) is a rare and highly aggressive plasma cell malignancy, often associated with complex genetic abnormalities. There is currently no standard treatment regimens, and conventional therapies for multiple myeloma are typically used. While targ...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.10.2025
ISIN: US60770K1079
Moderna Inc
MRNA
LISTED
NASDAQ
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
News Preview
CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. The details of the presentations are as follows:Late-Breaking Oral...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
ISIN: US24661P8077
Delcath Systems, Inc.
DCTH
LISTED
NASDAQ
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
News Preview
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for the quarter ended September 30, 2025, and updated 2025 full-year revenue guidance.
Preliminary Third Quarter Financial Results (unaudited)
Total...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
ISIN: US24661P8077
Delcath Systems, Inc.
DCTH
LISTED
NASDAQ
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
News Preview
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the results of the CHOPIN randomized Phase 2 clinical trial (CHOPIN Trial) presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, from Leiden University Medical Cente...
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
SMLR Deadline: SMLR Investors Have Opportunity to Lead Semler Scientific, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Semler Scientific, Inc. (NASD...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for the treatment...
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
News Preview
First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients with muscle-invasive bladder cancer
Unprecedented survival results from pivotal Phase 3 EV-303 trial...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
ISIN: JP3475350009
Daiichi Sankyo Co Ltd
45680
LISTED
XJPX
ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
News Preview
Positive results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting (before surgery) demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response (pCR) rate when compared with dose-...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 60% and reduced the risk of death by 50% when given before and after surgery (radical cystectomy) versus sur...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
ISIN: JP3475350009
Daiichi Sankyo Co Ltd
45680
LISTED
XJPX
ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial
News Preview
Positive results from the DESTINY-Breast05 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) compared to trastuzumab emtansine (T-DM1) as a post-neoadjuvant treatment (after surgery) in patients with HER2 positive ear...
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US05380C1027
AVITA Medical Inc
RCEL
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AVITA Medical, Inc. ("Avita" or the "Company") (NASDAQ: RCEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines - CYTK
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate ("Cytokinetics" or the "Company") (NASDAQ: CYTK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-fr...
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US69380Q1076
PACS Group, Inc.
PACS
LISTED
NYSE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PACS Group, Inc. - PACS
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PACS Group, Inc. ("PACS" or the "Company") (NYSE: PACS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US5171251003
Larimar Therapeutics Inc
LRMR
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US8753721047
Tandem Diabetes Care Inc
TNDM
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tandem Diabetes Care, Inc. - TNDM
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ: TNDM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATYR
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Tho...
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in LifeMD, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFMD
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. ("LifeMD" or the "Company") (NASDAQ: LFMD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those...
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US0162551016
Align Technology Inc
ALGN
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Align Technology, Inc. - ALGN
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Align Technology, Inc. ("Align" or the "Company") (NASDAQ: ALGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. ...
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US05463X1063
AxoGen Inc
AXGN
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US86627R1023
Summit Therapeutics Inc
SMMT
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US00847X1046
Agios Pharmaceuticals Inc
AGIO
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. ...
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Semler Scientific, Inc. of Class Action Lawsuit and Upcoming Deadlines - SMLR
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Semler Scientific, Inc. ("Semler" or the "Company") (NASDAQ: SMLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7...
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
Pomerantz Law Firm Announces the Filing of a Class Action Against Nutex Health Inc. and Certain Officers - NUTX
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nutex Health Inc. ("Nutex" or the "Company") (NASDAQ: NUTX) and certain officers. The class action, filed in the United States District Court for the Southern District of Texas, and docketed under 25...
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US68621F1021
Organogenesis Holdings Inc
ORGO
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. ...
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake Immunotherapeutics - MLTX
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MoonLake Immunotherapeutics ("Moonlake" or the "Company") (NASDAQ: MLTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRA
News Preview
NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Savara Inc. ("Savara" or the "Company") (NASDAQ: SVRA) and certain officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 2...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
